Atara Biotherapeutics (ATRA) Other Accumulated Expenses (2013 - 2026)

Atara Biotherapeutics' Other Accumulated Expenses history runs 14 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 64.83% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 64.83% YoY) and the FY2025 annual result came in at $82000.0, down 98.97% from the prior year.
• Other Accumulated Expenses was $2.9 million for Q1 2026 at Atara Biotherapeutics, up from $82000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $31.8 million in Q4 2023 and bottomed at $82000.0 in Q4 2025.
• A 5-year average of $11.7 million and a median of $8.0 million in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 7165.12% — and 2025, when it tumbled 98.97%.
• Atara Biotherapeutics' Other Accumulated Expenses stood at $25.0 million in 2022, then climbed by 27.34% to $31.8 million in 2023, then tumbled by 74.91% to $8.0 million in 2024, then tumbled by 98.97% to $82000.0 in 2025, then jumped by 3484.15% to $2.9 million in 2026.
• Business Quant data shows ATRA's Other Accumulated Expenses at $2.9 million in Q1 2026, $82000.0 in Q4 2025, and $144000.0 in Q3 2025.